Analysis of patent applications of heterocyclic compounds in China Pharmaceutical University 2010-2014

LI Hongxue; ZHANG Lei

doi:10.11665/j.issn.1000-5048.20160220

Journal of China Pharmaceutical University > 2016 > 47(2): 247-250. > DOI: 10.11665/j.issn.1000-5048.20160220

LI Hongxue, ZHANG Lei. Analysis of patent applications of heterocyclic compounds in China Pharmaceutical University 2010-2014[J]. Journal of China Pharmaceutical University, 2016, 47(2): 247-250. DOI: 10.11665/j.issn.1000-5048.20160220

Citation:

PDF (1132 KB)

Analysis of patent applications of heterocyclic compounds in China Pharmaceutical University 2010-2014

More Information

Graphical Abstract

Abstract

Abstract

According to “2015 State of Innovation” released by Thomson Reuters, China Pharmaceutical University ranked the first in the field of heterocyclic compounds in 2010-2014 among innovation agencies in Asia. In order to fully understand the situation of the new drug research of this university, this paper analyzes its patent application from 2010 to 2014 in the field of heterocyclic compounds. The key applications were summarized. In summary, this university showed its advantage of high filings and high licensing rate in the field of heterocyclic compounds, yet with the shortcomings of low patent applications in PCT. Furthermore, suggestions have been made for the intellectual property management of this university.
- heterocyclic compounds,
- China Pharmaceutical University,
- patents,
- analysis,
- cyclin-dependent kinase,
- NO donor,
- Polo-like kinase,
- gambogic acid,
- multidrug resistance

FullText(HTML)

References (6)

References

[1]	Bai XG,Xu LX,et al.Advance in research of cyclin-dependent kinase 2 inhibitors based on the structures of target proteins [J].Chin New Drugs J(中国新药杂志),2011, 20(17):1667-1672.
[2]	Zhang YH, Peng SX. Advances in the research of nitric oxide-donating drugs[J].J China Pharm Univ(中国药科大学学报),2006,37(5):387-396.
[3]	Jiang SM,Wang ZX.Research progress of Polo-like kinase 1 and prognosis and treatment in human carcinomas[J].Mod Oncol现代肿瘤医学),2013,21(3):650-653.
[4]	Feng F,Liu WY,Guo QL,et al.Anti-tumor QSAR of gambogic acid analogues[J].J China Pharm Univ(中国药科大学学报),2007,38(4):311-314.
[5]	Zhou ZT,Wang JW.PhaseⅠhuman tolerability trial of gambogic acid[J].Chin New Drugs J(中国新药杂志),2007,16(1):79-82.
[6]	Lu T,Lu S,Li HF,et al.Advances and prospects on signal transduction pathways in tumor and R&D of the related drugs(I)[J].J China Pharm Univ(中国药科大学学报),2008,39(3):193-199.

Cited By

Get Citation

PDF

XML

Article views (1077) PDF downloads (2155)

Turn off MathJax

Article Contents

Abstract

References

Analysis of patent applications of heterocyclic compounds in China Pharmaceutical University 2010-2014

Abstract

References

Catalog

Export File

Citation

Format

Content